This educational program is intended for neurologists, epileptologists, and other healthcare professionals specializing in the care of patients with epilepsy.
•  Back to top

Upon completion of this activity, participants should be better able to:

• Describe the prevalence and burden of epilepsy across pediatric, female, and elderly populations
• Understand the most recent strategies regarding the long-term management of epilepsy
• Recognize the impact of age and gender on the selection of AEDs
• List the available pharmacologic treatments for epilepsy and their associated risks and benefits across the lifetime of a patient with epilepsy

•  Back to top

This activity consists of a downloadable slide presentation with audio. This program takes approximately 1 hour to complete.
•  Back to top

The University of Cincinnati designates this educational activity for a maximum of 1 AMA PRA Category 1 credit(s)™. Physicians should claim credit commensurate with the extent of their participation in the activity.
•  Back to top

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. This activity has been planned and implemented in accordance with the Essentials and Policies of the Accreditation Council for Continuing Medical Education (ACCME). The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians. The University of Cincinnati takes responsibility for the content, quality, and scientific integrity of this CME activity.
•  Back to top

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. This activity may contain off-label use discussions of the following agents: gabapentin, lamotrigine and levetiracetam. The University of Cincinnati and SynerMed^® Communications do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati and SynerMed^® Communications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
•  Back to top

The University of Cincinnati is committed to offering CME programs that promote improvements of quality in healthcare and are developed free of the control of commercial interests. Faculty and course directors have disclosed all relevant financial relationships with commercial companies, and the University of Cincinnati has a process in place to resolve any conflict of interest. The University of Cincinnati also requires that faculty members disclose any discussion of off-label or investigational uses included in their presentations. Disclosure of a relationship is not intended to suggest or condone bias in a presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Michael Privitera, MD, (Program Chair), receives research support from the following sources: Johnson & Johnson, National Institutes of Health, Ortho-McNeil and UCB Pharma. He is a speaker for the following speakers’ bureaus: GlaxoSmithKline, Janssen-Cilag, Ortho-McNeil, Pfizer, and UCB Pharma and a consultant for the following pharmaceutical companies: GlaxoSmithKline, Ortho-McNeil, Pfizer, Schwarz Pharma, and UCB Pharma.

R. Eugene Ramsay, MD, FAAN, receives research support from the following sources: Abbott Laboratories, GlaxoSmithKline, IVAX, Ortho-McNeil, Pfizer, Schwarz Pharma and UCB Pharma. He is a speaker for the following speakers’ bureaus: Abbott Laboratories, Cyberonics, GlaxoSmithKline, Ortho-McNeil, Pfizer, and UCB Pharma and is a consultant for the following pharmaceutical companies: Abbott Laboratories, Cyberonics, GlaxoSmithKline, IVAX, Ortho-McNeil, Ovation Pharmaceuticals, Pfizer, Schwarz Pharma and UCB Pharma.

Raman Sankar, MD, PhD, receives research support from Valeant Pharmaceuticals and is a consultant and/or speaker for Cyberonics, GlaxoSmithKline, Ortho-McNeil Neurologics, National Institutes of Health, National Institute of Neurological Disorders and Stroke, UCB Pharma and Valeant Pharmaceuticals.

Georgia D. Montouris, MD (Clinical Content Reviewer), is a speaker for the following speakers’ bureaus: Abbott Laboratories, GlaxoSmithKline, Ortho-McNeil Janssen Scientific Affairs LLC, Pfizer, and UCB Pharma.

Stefanie Stendardo (Medical Writer) has nothing to disclose.
•  Back to top

The University of Cincinnati and SynerMed^® Communications staff involved in the development of this activity have no financial relationships with any commercial interest that are relevant to this activity. The information presented in this CME program represents the views and opinions of the individual presenters and does not constitute the opinion or endorsement of, or promotion by, the University of Cincinnati. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, US Food and Drug Administration—approved uses and any off-label uses.
•  Back to top

There are no fees for participating and receiving CME credit for this activity. During the period September 30, 2007 through September 30, 2008 participants must (1) read the educational objectives and faculty disclosures, (2) study the educational activity, (3) complete the posttest by recording the best answer to each question, (4) complete the evaluation form, and (5) mail or fax the evaluation form with answer key to the University of Cincinnati or complete the posttest and evaluation on-line by clicking here. A certificate of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your certificate of credit will be mailed to you within 3 – 5 weeks.
•  Back to top